10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
December 2024 in “International Journal of Dermatology” JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
15 citations
,
December 2020 in “Pharmacology Research & Perspectives” Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
3 citations
,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
1 citations
,
May 2023 in “Biochemical and Biophysical Research Communications” Blocking DKK1 with siRNA can improve hair growth.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
21 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.